A share price of Y-Mabs Therapeutics Inc [YMAB] is currently trading at $5.00, up 1.63%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The YMAB shares have gain 7.07% over the last week, with a monthly amount drifted -17.22%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Y-Mabs Therapeutics Inc [NASDAQ: YMAB] stock has seen the most recent analyst activity on November 18, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $23. Previously, Cantor Fitzgerald started tracking the stock with Overweight rating on August 16, 2024, and set its price target to $20. On June 28, 2024, Truist initiated with a Buy rating and assigned a price target of $21 on the stock. Wedbush upgraded its rating to a Outperform and increased its price target to $13 on May 10, 2023. Guggenheim downgraded its rating to a Neutral. Morgan Stanley downgraded its rating to Underweight for this stock on January 27, 2023, but kept the price target unchanged to $4. In a note dated January 05, 2023, Cowen downgraded an Market Perform rating on this stock.
Y-Mabs Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $4.25 and $17.78. Currently, Wall Street analysts expect the stock to reach $15.5 within the next 12 months. Y-Mabs Therapeutics Inc [NASDAQ: YMAB] shares were valued at $5.00 at the most recent close of the market. An investor can expect a potential return of 210.0% based on the average YMAB price forecast.
Analyzing the YMAB fundamentals
Trailing Twelve Months sales for Y-Mabs Therapeutics Inc [NASDAQ:YMAB] were 87.69M which represents 13.41% growth. Gross Profit Margin for this corporation currently stands at 0.83% with Operating Profit Margin at -0.36%, Pretax Profit Margin comes in at -0.34%, and Net Profit Margin reading is -0.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.25, Equity is -0.31 and Total Capital is -0.32. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.83 points at the first support level, and at 4.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 5.10, and for the 2nd resistance point, it is at 5.19.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Y-Mabs Therapeutics Inc [NASDAQ:YMAB] is 4.16. As well, the Quick Ratio is 3.85, while the Cash Ratio is 2.84. Considering the valuation of this stock, the price to sales ratio is 2.58, the price to book ratio is 2.44.
Transactions by insiders
Recent insider trading involved Rossi Michael J, PRESIDENT & CEO, that happened on Mar 07 ’25 when 3917.0 shares were sold. CHIEF BUSINESS OFFICER, Gad Thomas completed a deal on Mar 07 ’25 to sell 10810.0 shares. Meanwhile, Officer Rajah Vignesh bought 4946.0 shares on Mar 07 ’25.
